F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: F-18-Tetrafluoroborate PET/CT.
- Who it may be relevant to
- Registry conditions: Thyroid Cancer, Differentiated Thyroid Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.
Interventions
- Diagnostic test F-18-Tetrafluoroborate PET/CT
F-18-Tetrafluoroborate whole body PET/CT
Primary outcome measures
- Diagnostic accuracy of F-18-TFB PET/CT [Time frame: From enrollment of the first patient, 9 months]
Secondary outcome measures (3)
- F-18 TFB PET/CT positivity [Time frame: From enrollment of the first patient, 9 months]
- Correlation Between 18F-TFB PET/CT SUVmax (g/mL) and Serum Thyroglobulin Concentration (ng/mL) [Time frame: From enrollment of the first patient, 9 months]
- Correlation Between 18F-TFB PET/CT SUVmax (g/mL) and Serum Anti-Thyroglobulin Levels (IU/mL) [Time frame: From enrollment of the first patient, 9 months]
Eligibility criteria
Inclusion criteria
- Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
- Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up
- Negative or equivocal I-131 whole-body scan findings
- Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status)
- Giving written informed consent
Exclusion criteria
- Age under 18 years
- Pregnancy or breastfeeding
- Failure to provide written informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Turkey (Türkiye) · 2 centers
- Ankara University Medical School Nuclear Medicine Department — Ankara
- Hacettepe University Medical School Nuclear Medicine Department — Ankara
Identifiers
NCT: NCT07436455 · i06-456-25